関連レポート

出版元：Transparency Market Research  出版元について

発行年：2024年7月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 146ページになります。

商品コード：TMR327

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

膵臓がん治療の世界市場規模は2023年で29億ドル、2034年に102億ドル、市場の平均年成長率は12.4%にて増加する見込みです。

当レポートでは、膵臓がん治療の市場予測-2034年、各種セグメント別市場分析(治療タイプ別、適応症タイプ別、国地域別、等)、パイプライン分析、主要製品/ブランド分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■膵臓がん治療の世界市場予測2020-2034年
・市場規模(US$)

■治療タイプ別、市場-2034年
・化学療法
・免疫療法
・ホルモン療法
・外科療法
・放射線療法
・標的療法
※(市場規模US$)　

■適応症タイプ別、市場-2034年
・外分泌
・内分泌
※(市場規模US$)　

■エンドユーザー別、市場-2034年
・病院
・腫瘍科クリニック
・その他（研究機関など）
※(市場規模US$)　

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・ASEAN、韓国
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス
パイプライン分析
主要製品/ブランド分析
主要な合併、買収

■膵臓がん治療の主要企業プロフィール動向
Pfizer Inc.
Novartis AG
Eli Lilly and Company
Bristol-Myers Squibb Company
Zydus Cadilla
Myriad Genetics Inc.
F-Hoffmann-La Roche AG
PharmaCyte Biotech, Inc.
Teva Pharmaceutical Industries Ltd.
（全146頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Pancreatic Cancer Treatment Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Pancreatic Cancer Treatment Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Pancreatic Cancer Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2020-2034
6.3.1. Chemotherapy
6.3.2. Immunotherapy
6.3.3. Hormone Therapy
6.3.4. Surgery
6.3.5. Radiation Therapy
6.3.6. Targeted Therapy
6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Pancreatic Cancer Treatment Market Analysis and Forecast, by Indication Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication Type, 2020-2034
7.3.1. Exocrine
7.3.2. Endocrine
7.4. Market Attractiveness Analysis, by Indication Type

8. Global Pancreatic Cancer Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals
8.3.2. Oncology Clinics
8.3.3. Others (Research Institutes, etc.)
8.4. Market Attractiveness Analysis, by End-user

9. Global Pancreatic Cancer Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Pancreatic Cancer Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2020-2034
10.3.1. Chemotherapy
10.3.2. Immunotherapy
10.3.3. Hormone Therapy
10.3.4. Surgery
10.3.5. Radiation Therapy
10.3.6. Targeted Therapy
10.4. Market Value Forecast, by Indication Type, 2020-2034
10.4.1. Exocrine
10.4.2. Endocrine
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals
10.5.2. Oncology Clinics
10.5.3. Others (Research Institutes, etc.)
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Treatment Type
10.7.2. By Indication Type
10.7.3. By End-user
10.7.4. By Country

11. Europe Pancreatic Cancer Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2020-2034
11.3.1. Chemotherapy
11.3.2. Immunotherapy
11.3.3. Hormone Therapy
11.3.4. Surgery
11.3.5. Radiation Therapy
11.3.6. Targeted Therapy
11.4. Market Value Forecast, by Indication Type, 2020-2034
11.4.1. Exocrine
11.4.2. Endocrine
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals
11.5.2. Oncology Clinics
11.5.3. Others (Research Institutes, etc.)
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Treatment Type
11.7.2. By Indication Type
11.7.3. By End-user
11.7.4. By Country/Sub-region

12. Asia Pacific Pancreatic Cancer Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2020-2034
12.3.1. Chemotherapy
12.3.2. Immunotherapy
12.3.3. Hormone Therapy
12.3.4. Surgery
12.3.5. Radiation Therapy
12.3.6. Targeted Therapy
12.4. Market Value Forecast, by Indication Type, 2020-2034
12.4.1. Exocrine
12.4.2. Endocrine
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals
12.5.2. Oncology Clinics
12.5.3. Others (Research Institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Treatment Type
12.7.2. By Indication Type
12.7.3. By End-user
12.7.4. By Country/Sub-region

13. Latin America Pancreatic Cancer Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2020-2034
13.3.1. Chemotherapy
13.3.2. Immunotherapy
13.3.3. Hormone Therapy
13.3.4. Surgery
13.3.5. Radiation Therapy
13.3.6. Targeted Therapy
13.4. Market Value Forecast, by Indication Type, 2020-2034
13.4.1. Exocrine
13.4.2. Endocrine
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals
13.5.2. Oncology Clinics
13.5.3. Others (Research Institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Treatment Type
13.7.2. By Indication Type
13.7.3. By End-user
13.7.4. By Country/Sub-region

14. Middle East & Africa Pancreatic Cancer Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Treatment Type, 2020-2034
14.3.1. Chemotherapy
14.3.2. Immunotherapy
14.3.3. Hormone Therapy
14.3.4. Surgery
14.3.5. Radiation Therapy
14.3.6. Targeted Therapy
14.4. Market Value Forecast, by Indication Type, 2020-2034
14.4.1. Exocrine
14.4.2. Endocrine
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals
14.5.2. Oncology Clinics
14.5.3. Others (Research Institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Treatment Type
14.7.2. By Indication Type
14.7.3. By End-user
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Pfizer Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Novartis AG
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Eli Lilly and Company
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Bristol-Myers Squibb Company
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Zydus Cadilla
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Myriad Genetics Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. F-Hoffmann-La Roche AG
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. PharmaCyte Biotech, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Teva Pharmaceutical Industries Ltd.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview

List of Tables

Table 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 02: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 03: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 04: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Region, 2020-2034

Table 05: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country, 2020-2034

Table 06: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 07: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 08: North America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 09: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 10: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 11: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 12: Europe Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 13: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 14: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 15: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 16: Asia Pacific Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 17: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 18: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 19: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 20: Latin America Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

Table 21: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034

Table 23: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

Table 24: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

Figure 01: Global Non-insulin Therapies for Diabetes Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034

Figure 02: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Drug Class, 2023

Figure 03: Global Non-insulin Therapies for Diabetes Market Value Share, by Drug Class, 2023

Figure 04: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Route of Administration, 2023

Figure 05: Global Non-insulin Therapies for Diabetes Market Value Share, by Route of Administration, 2023

Figure 06: Global Non-insulin Therapies for Diabetes Market Revenue (US$ Bn), by Distribution Channel, 2023

Figure 07: Global Non-insulin Therapies for Diabetes Market Value Share, by Distribution Channel, 2023

Figure 08: Global Non-insulin Therapies for Diabetes Market Value Share, by Region, 2023

Figure 09: Global Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast, 2020-2034

Figure 10: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 11: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 12: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 13: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 14: Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 15: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 16: Global Non-insulin Therapies for Diabetes Market Value Share Analysis, by Region, 2023 and 2034

Figure 17: Global Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 18: North America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 19: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country, 2024-2034

Figure 20: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country, 2023 and 2034

Figure 21: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 22: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 23: North America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 24: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 25: North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 26:North America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 27: Europe Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 28: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 29: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 30: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 31: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 32: Europe Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 33: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 34: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 35: Europe Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 36: Asia Pacific Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 37: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 38: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 39: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 40: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 41: Asia Pacific Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 42: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 43: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 44: Asia Pacific Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 45: Latin America Non-insulin Therapies for Diabetes Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 46: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 47: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 48: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 49: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 50: Latin America Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 51: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 52: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 53: Latin America Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Figure 54: Middle East & Africa Non-insulin Therapies for Diabetes Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 55: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 56: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 57: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Drug Class, 2023 and 2034

Figure 58: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Route of Administration, 2023 and 2034

Figure 59: Middle East & Africa Non-insulin Therapies for Diabetes Market Value Share Analysis, by Distribution Channel, 2023 and 2034

Figure 60: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Region, 2024-2034

Figure 61: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Route of Administration, 2024-2034

Figure 62: Middle East & Africa Non-insulin Therapies for Diabetes Market Attractiveness Analysis, by Distribution Channel, 2024-2034

△ 一番上に戻る